Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 3/20 | 0.49 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31180735 | 1.00 | MDM2 (0.55) | MDM2KMT2AMDM4TP53IDO1 | |
| SCHEMBL29400825 | 1.00 | MDM2 (0.55) | MDM2KMT2AMDM4TP53IDO1 | |
| SCHEMBL1300076 | 1.00 | MDM2 (0.55) | MDM2KMT2AMDM4TP53IDO1 | |
| SCHEMBL29594390 | 1.00 | MDM2 (0.55) | MDM2KMT2AMDM4TP53IDO1 | |
| SCHEMBL29362665 | 0.96 | MDM2 (0.57) | MDM2KMT2AMDM4TP53TLR2 | |
| SCHEMBL14039221 | 0.96 | MDM2 (0.57) | MDM2KMT2AMDM4TP53TLR2 | |
| SCHEMBL30385460 | 0.96 | MDM2 (0.57) | MDM2KMT2AMDM4TP53TLR2 | |
| SCHEMBL29383813 | 0.96 | MDM2 (0.57) | MDM2KMT2AMDM4TP53TLR2 | |
| SCHEMBL30645673 | 0.96 | MDM2 (0.57) | MDM2KMT2AMDM4TP53TLR2 | |
| SCHEMBL4612515 | 0.96 | MDM2 (0.57) | MDM2KMT2AMDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3700545-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | Southern Research Institute (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-9676785-B2 | HCV protease inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-06-13 | — | — | US | disclosed |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140323465-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2014-10-30 | — | — | US | disclosed |
| US-8778877-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | FERRING B.V. | 2008-10-16 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7335677-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING B.V. (NL) | 2008-02-26 | — | — | US | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050043299-A1 | Inhibitors of dipeptidyl peptidase iv | FERRING B. V. | 2005-02-24 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
| EP-1446116-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING B.V. (NL) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003035057-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING B.V. (NL) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323465-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | MDM2 1843/4885KMT2A 3993/4885MDM4 2164/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | MDM2 917/4885KMT2A 1219/4885MDM4 1166/4885 |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | MDM2 1843/4885KMT2A 3993/4885MDM4 2164/4885 |
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | MDM2 72/4885KMT2A 1160/4885MDM4 1746/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | MDM2 2032/4885KMT2A 4429/4885MDM4 2087/4885 |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | MDM2 1843/4885KMT2A 3993/4885MDM4 2164/4885 |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | TGFB1, TGFB2, SMAD3 | MDM2 993/4885KMT2A 1644/4885MDM4 1715/4885 |
| US-20050043299-A1 | Inhibitors of dipeptidyl peptidase iv | DPP4, DPP9, DPP3 | MDM2 2606/4885KMT2A 3490/4885MDM4 4447/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | MDM2 72/4885KMT2A 1160/4885MDM4 1746/4885 |
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | PREP, PEPD, DPP4 | MDM2 2492/4885KMT2A 3682/4885MDM4 4625/4885 |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | TGFB1, TGFB2, SMAD3 | MDM2 993/4885KMT2A 1644/4885MDM4 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.